<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01252628</url>
  </required_header>
  <id_info>
    <org_study_id>PX-866-003</org_study_id>
    <nct_id>NCT01252628</nct_id>
  </id_info>
  <brief_title>Phase 1 and 2 Study of PX-866 and Cetuximab</brief_title>
  <official_title>Phase 1/2 Study of PX-866 and Cetuximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cascadian Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 1/2 open-label study is to determine the safety and efficacy of a
      cetuximab and PX-866 combination treatment. In the Phase 1 part of the study, the dose of
      PX-866 to be given in combination with cetuximab will be determined in patients with
      incurable metastatic CRC or incurable progressive, recurrent or metastatic SCCHN. The Phase 2
      part of the study is a randomized evaluation of the antitumor activity and safety of PX-866
      in combination with cetuximab versus cetuximab alone in patients with either incurable
      metastatic CRC who have a history of progression or recurrence following prior irinotecan and
      oxaliplatin containing regimens or are intolerant of irinotecan (Group 1) or incurable
      progressive, recurrent or metastatic SCCHN (Group 2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 will determine the maximally tolerated or recommended dose of PX-866 to be given
      orally on Days 1-21 in combination with cetuximab 250 mg/m2 administered IV weekly on Days 1,
      8, and 15 of a 21-day cycle. All patients will receive an initial loading dose of 400 mg/m2
      cetuximab rather than 250 mg/m2 on Cycle 1 Day 1. Patients may receive premedication with an
      H1 antagonist per the cetuximab package insert. Up to 3 dose levels of PX-866 will be
      evaluated to determine the MTD/RD in cohorts of up to 6 patients using a standard 3+3
      dose-escalation design. At least 6 patients will be treated at the MTD/RD. All patients in
      Phase 1 will be required to undergo PK assessments during Cycle 1 Week 3 to measure cetuximab
      levels. Exploratory PD assessments will include evaluation of changes in levels of fasting
      C-peptide as well as changes in EGFR and PI-3K signaling pathways in peripheral blood
      mononuclear cells (PBMC) and platelets. Additional optional evaluations will include changes
      in EGFR and PI-3K signaling in paired tumor biopsies provided before and after one cycle of
      treatment. All patients will be asked, but not required, to provide an archived tumor biopsy
      sample for evaluation for potential biomarkers of response to PX-866 and cetuximab.

      Phase 2 is an open-label, randomized evaluation of the antitumor activity and safety of
      PX-866 administered orally or via PEG tube (if applicable) at the MTD/RD in combination with
      cetuximab, versus cetuximab alone in cetuximab-naïve patients with incurable metastatic CRC
      who have a history of progression or recurrence following prior irinotecan and oxaliplatin
      containing regimens or are intolerant of irinotecan (Group 1) or patients with incurable
      progressive, recurrent or metastatic SCCHN (Group 2). Seventy two evaluable patients (36
      patients per arm) will be evaluated per indication. Patients will be randomized 1:1 to
      receive PX-866 + cetuximab or cetuximab alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The evaluation of antitumor effects of PX-866 in combination with cetuximab versus cetuximab in patients with incurable metastatic colorectal cancer and/or patients with incurable progressive, recurrent or metastatic SCC of the head and neck.</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">178</enrollment>
  <condition>Incurable Metastatic Colorectal Carcinoma</condition>
  <condition>Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>PX-866 (SCCHN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 (Squamous Cell Carcinoma of the Head and Neck)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab (SCCHN)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase 2 (Squamous Cell Carcinoma of the Head and Neck)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PX-866 (CRC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 (Colorectal Carcinoma)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab (CRC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase 2 (Colorectal Carcinoma)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PX-866 (SCCHN)</intervention_name>
    <description>PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.</description>
    <arm_group_label>PX-866 (SCCHN)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab (SCCHN)</intervention_name>
    <description>Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.</description>
    <arm_group_label>PX-866 (SCCHN)</arm_group_label>
    <arm_group_label>Cetuximab (SCCHN)</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PX-866 (CRC)</intervention_name>
    <description>PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.</description>
    <arm_group_label>PX-866 (CRC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab (CRC)</intervention_name>
    <description>Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.</description>
    <arm_group_label>PX-866 (CRC)</arm_group_label>
    <arm_group_label>Cetuximab (CRC)</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years at time of consent

          -  Use of a medically accepted form of contraception from the time of consent to
             completion of all follow-up study visits

          -  If female of child-bearing potential, negative pregnancy test

          -  Signed an informed consent

          -  Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST)

          -  Documentation available for last prior systemic treatment including dates of
             treatment, best response to treatment, duration of best response, and reason for
             discontinuation of treatment

          -  Eastern Cooperative Oncology Group (ECOG) 0 or 1

          -  Group 1: Patients with incurable metastatic CRC with a history of progression or
             recurrence following prior irinotecan and oxaliplatin containing regimens. Patients
             who have a history of intolerance of irinotecan based therapy or ineligibility to
             receive irinotecan are also eligible as long as they have received a prior oxaliplatin
             containing regimen.

          -  Group 2: Patients with incurable SCCHN with a history of progression or recurrence
             following at least one prior platinum based chemotherapy or chemotherapy/radiation
             containing regimen. Patients who have a history of intolerance of platinum based
             therapy or history of ineligibility to receive a platinum based regimen are also
             eligible. SCCHN patients who received cetuximab as a radiosensitizer for locally
             advanced disease and completed treatment at least 6 months prior to start of study
             drug treatment are eligible

          -  In the opinion of the clinical investigator, life expectancy of greater than 3 months

          -  Adequate hematologic function

          -  Adequate hepatic function

          -  Creatinine level ≤1.5 x ULN

          -  Serum magnesium ≥ LLN.

        Exclusion Criteria:

          -  Has medical, social, or psychosocial factors that, in the opinion of the investigator,
             could impact safety or compliance with study procedures

          -  Is breastfeeding

          -  Treatment with any systemic chemotherapy, epidermal growth factor receptor (EGFR)
             inhibitor, radiation or experimental agent within 4 weeks of study drug dosing

          -  Received prior cetuximab, except as defined in inclusion criteria

          -  Previous treatment with a phosphatidylinositol 3-kinase (PI-3K) inhibitor

          -  Known human immunodeficiency virus (HIV)

          -  Poorly controlled diabetes mellitus (IFCC-HbA1C ≥ 53 mmol/mol or DCCT -HbA1C ≥ 7%)

          -  Kras mutation in codon 12 or 13 (CRC patients only)

          -  Known or suspected clinically active brain metastases. Previously treated and stable
             brain metastases are allowable. Stable brain metastases are defined as no change on CT
             scan or MRI for minimum of two months AND no change in steroid dose for a minimum of
             four weeks, unless change due to intercurrent infection or other acute event)

          -  Any other significant medical or psychiatric condition that in the opinion of the
             investigator renders the patient inadequate for participation

          -  History of severe hypersensitivity to cetuximab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Hausman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cascadian Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Hematology and Oncology Assocs.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Cancer Care</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monterey Bay Oncology</name>
      <address>
        <city>Monterey</city>
        <state>California</state>
        <zip>93940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura County Hematology Oncology Specialists</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Colorado Health Care System - (Denver VA)</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University - Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Community Oncology Network</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Specialties</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pasco Pinellas Cancer Center</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peachtree Hematology-Oncology Consultants</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis Cancer Care LLP</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUSC Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Sammons</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Seton Williamson</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Cancer Institute</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Basin Hematology and Oncology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Regional Health Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Cancer Centre of Health Sciences North</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Sciences Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles-LeMoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cité de la Santé de Laval</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7M 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital Research Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <disposition_first_submitted>April 30, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 19, 2015</disposition_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRC</keyword>
  <keyword>SCCHN</keyword>
  <keyword>PX-866</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>ERBITUX</keyword>
  <keyword>Colon</keyword>
  <keyword>Head and Neck</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Squamous cell carcinoma</keyword>
  <keyword>PI-3K</keyword>
  <keyword>PI3 kinase</keyword>
  <keyword>PI3K</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

